Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Radioimmunotherapy With Tositumomab and Iodine-131 Tositumomab for Low-Grade Non-Hodgkin Lymphoma: Nursing Implications

Judith M. Estes
Kathleen J. Clapp
ONF 2004, 31(6), 1119-1126 DOI: 10.1188/04.ONF.1119-1126

Purpose/Objectives: To review radioimmunotherapy approaches for low-grade non-Hodgkin lymphoma (NHL) with a focus on tositumomab and iodine-131 tositumomab (Bexxar®, Corixa Corporation, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA). Nursing implications for Bexxar therapy are reviewed, including radiation safety, patient education, and the management of therapy-related toxicities.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or